Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.50 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880785 | 1.00 | TGFBR1 (0.52) | TGFBR1ADORA2AADORA1NAMPTDYRK1A | |
| SCHEMBL21730262 | 0.83 | ADORA2A (0.67) | ADORA2AADORA1ADORA2B | |
| SCHEMBL22552120 | 0.82 | ADORA2A (0.62) | TGFBR1ADORA2AADORA1DYRK1AADORA2B | |
| SCHEMBL30880782 | 0.82 | ADORA2A (0.62) | TGFBR1ADORA2AADORA1DYRK1AADORA2B | |
| SCHEMBL22551856 | 0.78 | ADORA2A (0.63) | TGFBR1ADORA2AADORA1ADORA2B | |
| SCHEMBL29907719 | 0.78 | ADORA2A (0.63) | TGFBR1ADORA2AADORA1ADORA2B | |
| SCHEMBL27399209 | 0.77 | TGFBR1 (0.60) | TGFBR1ADORA2AADORA1NAMPTDYRK1A | |
| SCHEMBL4585883 | 0.75 | ADORA2A (0.65) | ADORA2AADORA1ADORA2B | |
| SCHEMBL29987316 | 0.75 | ADORA2A (0.65) | ADORA2AADORA1ADORA2B | |
| SCHEMBL22270736 | 0.74 | TGFBR1 (0.53) | TGFBR1ADORA2AADORA1NAMPTDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | TGFBR1 2449/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | TGFBR1 2449/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | TGFBR1 2449/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | TGFBR1 2449/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | TGFBR1 2449/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.